Randomized, double-blind, placebo-controlled, 3-arm, 36 weeks parallel-group study to evaluate the safety and tolerability of ORY-2001 in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS)
Latest Information Update: 10 Dec 2021
At a glance
- Drugs Vafidemstat (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms SATEEN
- Sponsors Oryzon
- 15 Oct 2021 Results (N=18) presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 13 Oct 2021 Results (n=18) presented in an Oryzon Media Release.
- 13 Oct 2021 According to an Oryzon media release, data were presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, ECTRIMS-2021.